AI Article Synopsis

  • The study aimed to identify factors that predict ongoing disease activity in patients with neovascular age-related macular degeneration (nAMD) after receiving treatments with anti-VEGF medications in real-world settings.
  • A retrospective analysis of the PROOF study included data from 600 treatment-naive patients who received their first anti-VEGF treatment between 2017 and 2019, with follow-ups at 12 and 24 months.
  • Results showed that a significant percentage of patients still experienced retinal fluid at 12 and 24 months, with fibrovascular pigment epithelial detachments and persistent retinal fluid after the initial treatment phase being strong predictors of ongoing disease activity.

Article Abstract

Introduction: The aim of this study was to investigate the predictive factors for persistent disease activity following anti-vascular endothelial growth factors (anti-VEGF) and their long-term effects in patients to be treated for neovascular age-related macular degeneration (nAMD) under real-world conditions.

Methods: Retrospective data analysis of the PROOF study, a multi-center real-world retrospective chart review conducted across Korea in patients with nAMD included treatment-naive patients with nAMD who received first anti-VEGF (ranibizumab, bevacizumab, or aflibercept) between January 2017 and March 2019 was performed. All 600 patients (cohort 1) had a minimum follow-up of 12 months of which 453 patients (cohort 2) were followed-up for 24 months from baseline.

Results: At month 12 after anti-VEGF therapy, 58.10% (95% confidence interval [CI]: 54.09, 62.12) of patients and at month 24, 66.02% of patients continued to have persistent retinal fluid. At both months 12 and 24, predictive factors for persistent disease activity were fibrovascular pigment epithelial detachments (PED) (P = 0.0494) and retinal fluid at month 3 after loading phase (P = 0.0082). The mean changes in visual acuity were + 6.2, + 10.1, and + 13.3 letters and in the central subfield thickness were - 79.1 µm, - 96.3 µm, and - 134.4 µm at 12 months from baseline, in the bevacizumab, aflibercept, and ranibizumab groups, respectively.

Conclusions: The presence of retinal fluid after loading phase and fibrovascular PED were predictors of persistent disease activity after at least 1 year of anti-VEGF treatment.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11493875PMC
http://dx.doi.org/10.1007/s40123-024-01021-xDOI Listing

Publication Analysis

Top Keywords

disease activity
16
persistent disease
12
retinal fluid
12
anti-vegf treatment
8
neovascular age-related
8
age-related macular
8
macular degeneration
8
proof study
8
predictive factors
8
factors persistent
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!